A Phase I-II Trial of Everolimus and Sorafenib in Patients With Recurrent High-Grade Gliomas
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
- 26 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 06 Nov 2015 Status changed from recruiting to not yet recruiting, as reported by ClinicalTrials.gov.